**Curis Inc. Reports Financial Results and Operational Updates in Annual Filing**
Curis, Inc., a biotechnology company focused on developing cancer treatments, released its 10-K filing, detailing its financial performance and operational activities for the fiscal year ending December 31, 2025. The company reported a net loss of $7.6 million, which included a one-time non-cash gain of $27.2 million from the release of liability related to the sale of future royalties associated with sale of assets. This compares favorably to the $43.4 million net loss reported for the previous fiscal year. The company's revenue, primarily from royalties on net sales of Erivedge, decreased by 13% to $9.4 million.
The company's research and development expenses decreased by 27% to $28.3 million, while general and administrative expenses decreased by 16% to $14.0 million. These decreases were attributed to lower employee-related, clinical, manufacturing, consulting, research, facility, and travel costs. As of December 31, 2025, Curis had $5.1 million in cash and cash equivalents. In January 2026, the company completed a private placement for net proceeds of approximately $18.6 million.
Operationally, Curis is focusing on the development of emavusertib, an IRAK4 and FLT3 inhibitor. The company is currently evaluating emavusertib in a Phase 1/2 study in relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with ibrutinib, and in a Phase 2 study in chronic lymphocytic leukemia (CLL) with zanubrutinib. Monotherapy and combination studies of emavusertib in AML are substantially complete. The company has received Orphan Drug Designation from the FDA and European Commission for emavusertib in PCNSL, AML, and MDS.
The filing also included a cautionary note regarding the company's ability to continue as a going concern, citing recurring losses, negative cash flows, and the need for additional funding. The company stated that it will need to seek additional funding through equity financings, collaborations, or other strategic transactions. If sufficient funds are not available, the company may have to delay, reduce, or eliminate its research and development program for emavusertib, which would adversely affect its business prospects. As of March 20, 2026, there were 39,978,693 shares of the company’s common stock outstanding.
About CURIS INC
Curis, Inc. is a biotechnology company focused on developing targeted cancer therapies, primarily through small molecule inhibitors like emavusertib targeting IRAK4. It operates in immuno-oncology and precision oncology, collaborating with partners such as Aurigene and Genentech. The company advances drug candidates through preclinical and clinical trials, seeking regulatory approvals and licensing its technologies to generate revenue from royalties and milestone payments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.